Pfizer will acquire Icagen, Inc., one of its development and commercialization partners. The acquisition will cost $56 million for the 89% of Icagen shares that Pfizer does not currently own. In 2007, Pfizer and Icagen entered into a discovery and commercialization collaboration for the development of treatments for pain and related disorders utilizing sodium ion channels, which have the potential for fewer side effects. “We’re excited that Icagen, a global leader in pain research, will join P...